Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: a survey by the European Retinoblastoma group (EURbG)
Gespeichert in:
| Titel: | Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: a survey by the European Retinoblastoma group (EURbG) |
|---|---|
| Autoren: | Nikolaos E. Bechrakis, Maja Beck Popovic, Ida Russo, Yelena Diarra, Artur Klett, Katarzyna Pawinska-Wasikowska, Catriona Duncan, Helen Jenkinson, Eva Biewald, Beate Timmermann, Shani Caspi, Karel Svojgr, Hatice Tuba Atalay, Erika Maka, Martin Ebinger, Tomáš Kepák, Sonsoles San Roman Pacheco, Olga Rutynowska-Pronicka, Petra Ketteler, Doris Hadjistilianou, Floor Abbink, Annette C. Moll, Petra Ritter-Sovinz, Guilherme Castela, Francis L. Munier, Vicktoria Vishnevskia-Dai, François Doz, Nathalie Cassoux, Isabelle Aerts, Angelika Eggert, Nadezhda Fedorovna Bobrova, Ines B Brecht, Guillermo Chantada, Jelena Rascon, Sabine Dittner-Moormann, Enrico Opocher, Constantino Sábado Álvarez, Hayyam Kiratli, David Garcia Aldana, Madlen Reschke |
| Weitere Verfasser: | Institut Català de la Salut, [Dittner-Moormann S] Department of Pediatric Hematology and Oncology, University Duisburg-Essen, University Hospital Essen, Essen, Germany. [Reschke M] Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany. [Abbink FCH] Amsterdam UMC, Location VU University Medical Centre, Amsterdam, The Netherlands. [Aerts I] Institut Curie, PSL Research University and University of Paris, Paris, France. [Atalay HT] Gazi University School of Medicine, Ankara, Turkey. [Fedorovna Bobrova N] Filatov Eye Institute Odessa, Odessa, Ukraine. [Sábado Álvarez C] Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Quelle: | RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía instname Scientia Scientia. Dipòsit d'Informació Digital del Departament de Salut PEDIATRIC BLOOD & CANCER r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu Fundació Sant Joan de Déu Dittner-Moormann, S, Reschke, M, Abbink, F C H, Aerts, I, Atalay, H T, Fedorovna Bobrova, N, Biewald, E, Brecht, I B, Caspi, S, Cassoux, N, Castela, G, Diarra, Y, Duncan, C, Ebinger, M, Garcia Aldana, D, Hadjistilianou, D, Kepák, T, Klett, A, Kiratli, H, Maka, E, Opocher, E, Pawinska-Wasikowska, K, Rascon, J, Russo, I, Rutynowska-Pronicka, O, Sábado Álvarez, C, Pacheco, S S R, Svojgr, K, Timmermann, B, Vishnevskia-Dai, V, Eggert, A, Ritter-Sovinz, P, Bechrakis, N E, Jenkinson, H, Moll, A, Munier, F L, Popovic, M B, Chantada, G, Doz, F & Ketteler, P 2021, 'Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)', Pediatric Blood and Cancer, vol. 68, no. 6, e28963. https://doi.org/10.1002/pbc.28963 Pediatric blood & cancer, vol. 68, no. 6, pp. e28963 Pediatric blood & cancer., Hoboken : Wiley, 2021, vol. 68, iss. 6, art. no. e28963, p. [1-9]. |
| Verlagsinformationen: | Wiley, 2020. |
| Publikationsjahr: | 2020 |
| Schlagwörter: | Retinal Neoplasms, Medizin, childhood cancer, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors, chemotherapy, Enquestes, Eye Enucleation, metastasis, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Surveys and Questionnaires, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo, Antineoplastic Combined Chemotherapy Protocols, biomarker, Humans, Child, radiotherapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy, Retina - Càncer - Radioteràpia, RB1 gene, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires, Retinoblastoma, DISEASES::Neoplasms::Neoplasms::Neoplasms::Neoplasms::Neoplasms by Site::Eye Neoplasms::Retinal Neoplasms::Retinoblastoma, ENFERMEDADES::neoplasias::neoplasias::neoplasias::neoplasias::neoplasias por localización::neoplasias del ojo::neoplasias de la retina::retinoblastoma, Prognosis, Combined Modality Therapy, 3. Good health, Retina - Càncer - Quimioteràpia, Europe, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Chemotherapy, Adjuvant/methods, Child, Preschool, Combined Modality Therapy/methods, Radiotherapy, Adjuvant/methods, Retinal Neoplasms/pathology, Retinal Neoplasms/therapy, Retinoblastoma/pathology, Retinoblastoma/therapy, Chemotherapy, Adjuvant, Radiotherapy, Adjuvant, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado |
| Beschreibung: | Introduction: Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond natural limits of the eye may lead to metastatic disease which is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. Method: Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma group (EURbG) network. Extended information were gathered via personal Email communication. Results: Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. Conclusion: Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers. |
| Publikationsart: | Article Other literature type |
| Dateibeschreibung: | application/pdf |
| ISSN: | 1545-5017 1545-5009 |
| DOI: | 10.22541/au.160761774.49039452/v1 |
| DOI: | 10.1002/pbc.28963 |
| Zugangs-URL: | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pbc.28963 https://pubmed.ncbi.nlm.nih.gov/33720495 http://hdl.handle.net/10668/17353 https://hdl.handle.net/11351/7617 http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19278 https://hdl.handle.net/20.500.12530/67926 https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19278 https://www.authorea.com/users/382208/articles/498172-adjuvant-therapy-of-histopathological-risk-factors-of-retinoblastoma-in-europe-a-survey-by-the-european-retinoblastoma-group-eurbg https://d197for5662m48.cloudfront.net/doi/full/10.22541/au.160761774.49039452/v1 https://epublications.vu.lt/object/elaba:87515578/index.html https://www.narcis.nl/publication/RecordID/oai%3Apure.atira.dk%3Apublications%2Feb3016b6-108d-4607-a6e6-5c97f4e5debb https://www.ncbi.nlm.nih.gov/pubmed/33720495 https://research.vumc.nl/en/publications/adjuvant-therapy-of-histopathological-risk-factors-of-retinoblast https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28963 https://www.muni.cz/vyzkum/publikace/1786843 https://avesis.gazi.edu.tr/publication/details/414c08df-97af-439a-8b1b-70960bc95e9c/oai https://research.vumc.nl/en/publications/eb3016b6-108d-4607-a6e6-5c97f4e5debb https://serval.unil.ch/resource/serval:BIB_C745699D2ADF.P001/REF.pdf https://serval.unil.ch/notice/serval:BIB_C745699D2ADF http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_C745699D2ADF5 https://hdl.handle.net/10668/17353 https://onlinelibrary.wiley.com/doi/10.1002/pbc.28963 https://ruj.uj.edu.pl/xmlui/handle/item/290327 https://repository.vu.lt/VU:ELABAPDB87515578&prefLang=en_US |
| Rights: | CC BY NC |
| Dokumentencode: | edsair.doi.dedup.....2452008a1f17db6cc1a00716a9b3562d |
| Datenbank: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Introduction: Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond natural limits of the eye may lead to metastatic disease which is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. Method: Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma group (EURbG) network. Extended information were gathered via personal Email communication. Results: Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. Conclusion: Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers. |
|---|---|
| ISSN: | 15455017 15455009 |
| DOI: | 10.22541/au.160761774.49039452/v1 |